ASX 200 morning report – Interest rate rise hits Aussie share market
James Dunn
May 4, 2022
The S&P/ASX 200 (ASX: XJO) was muted in response to
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (ASX: XJO) was muted in response to
The S&P/ASX 200 (ASX: XJO) is set to open lower
The selling pressure continued on Wednesday with the S&P/ASX 200
The S&P/ASX 200 (ASX:XJO) finished down 0.6% on Friday as
Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) and ASX-listed
The Nanosonics Ltd (ASX: NAN) share price is sinking despite
ASX shares have been releasing some monster earnings in week
Surges from CSL Limited (ASX:CSL) and BHP Group Ltd (ASX:BHP)
Healthy earnings results from the likes of CSL (ASX:CSL) and
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
